Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production

José Herrera-Rodriguez, Aurora Signorazzi, Marijke Holtrop, Jacqueline de Vries-Idema, Anke Huckriede

Research output: Contribution to journalArticleAcademicpeer-review

36 Citations (Scopus)
985 Downloads (Pure)


The vast majority of commercially available inactivated influenza vaccines are produced from egg-grown or cell-grown live influenza virus. The first step in the production process is virus inactivation with β-propiolactone (BPL) or formaldehyde (FA). Recommendations for production of inactivated vaccines merely define the maximal concentration for both reagents, leaving the optimization of the process to the manufacturers. We assessed the effect of inactivation with BPL and FA on 5 different influenza virus strains. The properties of the viral formulation, such as successful inactivation, preservation of hemagglutinin (HA) binding ability, fusion capacity and the potential to stimulate a Toll-like receptor 7 (TLR7) reporter cell line were then assessed and compared to the properties of the untreated virus. Inactivation with BPL resulted in undetectable infectivity levels, while FA-treated virus retained very low infectious titers. Hemagglutination and fusion ability were highly affected by those treatments that conferred higher inactivation, with BPL-treated virus binding and fusing at a lower degree compared to FA-inactivated samples. On the other hand, BPL-inactivated virus induced higher levels of activation of TLR7 than FA-inactivated virus. The alterations caused by BPL or FA treatments were virus strain dependent. This data shows that the inactivation procedures should be tailored on the virus strain, and that many other elements beside the concentration of the inactivating agent, such as incubation time and temperature, buffer and virus concentration, have to be defined to achieve a functional product.
Original languageUndefined/Unknown
Pages (from-to)1630 - 1637
Number of pages8
Issue number12
Publication statusPublished - 14-Mar-2019


  • β-propiolactone, Formaldehyde, Vaccine, Influenza, Inactivation

Cite this